Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
|Articles|October 25, 2013
- Genitourinary Cancers
- Volume 1
- Issue 1
Immune Response in Patients with RCC
Author(s)Jeffrey A. Sosman, MD
Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses immune response in renal cell carcinoma.
Advertisement
Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses immune response in renal cell carcinoma.
The treatment of advanced renal cell carcinoma (RCC) remains a major challenge for clinicians.Read more > >
Articles in this issue
almost 13 years ago
Patient-Centered Management of Metastatic Renal Cell Carcinomaalmost 13 years ago
Expert Perspectives: Androgen-Deprivation Therapy in Prostate Canceralmost 13 years ago
Treatment of Advanced Renal Cell Carcinomaalmost 13 years ago
Treatment Pathways and Sequencing Strategies in CRPCalmost 13 years ago
Therapeutic Strategies for Managing Bone Health in Prostate Canceralmost 13 years ago
Immunotherapy in CRPCalmost 13 years ago
Factors in Choosing First-Line Targeted Therapy in RCCalmost 13 years ago
Frontline Treatment of Kidney Cancer With Pazopanib and Sunitinibalmost 13 years ago
Sequencing Agents to Treat Castration-Resistant Prostate CancerAdvertisement
Related to this article
FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Durability of PFS and OS Benefit vs. Historical Control
3
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5